reference/13198241

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/13198241

Outgoing Links

Predicate	Object
contentType	Clinical Trial\|Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	2258
issn	1097-0142 0008-543X
issueIdentifier	9
pageRange	2247-2258
publicationName	Cancer
startingPage	2247
bibliographicCitation	Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thürlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M; Arimidex Writing Committee; Investigators Committee Members. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 2001 Nov 01;92(9):2247–58. doi: 10.1002/1097-0142(20011101)92:9<2247::aid-cncr1570>3.0.co;2-y. PMID: 11745278.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1c7db903dccbb62d2ad7160f69c6b9b0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_37f25bd31177f3f3660837189c183029 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2732bb98d4d24b9c07dd92917d23749d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7914233b729b85cfa4395c7c76daee2a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_db3989703bf693b9dfa4263e7dad5c1f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c19a06fc851ef5dcaecaaeb29a662760 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_019eaf34d8b614fa137d3ad217554156 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e206bd35ee1a9c25cfce9f9ef416fb5d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_095d3b102c430db7a6df84db16f4c00b
date	2001-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1002/1097-0142%2820011101%2992:9%3C2247::aid-cncr1570%3E3.0.co%3B2-y https://pubmed.ncbi.nlm.nih.gov/11745278
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2771 https://portal.issn.org/resource/ISSN/1097-0142 https://portal.issn.org/resource/ISSN/0008-543X
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma
discusses	http://id.nlm.nih.gov/mesh/M0021024 http://id.nlm.nih.gov/mesh/M0014878 http://id.nlm.nih.gov/mesh/M0238999 http://id.nlm.nih.gov/mesh/M0021911 http://id.nlm.nih.gov/mesh/M0018586 http://id.nlm.nih.gov/mesh/M0018613 http://id.nlm.nih.gov/mesh/M0028300
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D013629Q000494 http://id.nlm.nih.gov/mesh/D011980Q000032 http://id.nlm.nih.gov/mesh/D014230Q000494 http://id.nlm.nih.gov/mesh/D018931Q000494 http://id.nlm.nih.gov/mesh/D011960Q000032 http://id.nlm.nih.gov/mesh/D009570Q000494 http://id.nlm.nih.gov/mesh/D001943Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D011379 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D013923Q000139 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D017698 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D000077384 http://id.nlm.nih.gov/mesh/D006470Q000139 http://id.nlm.nih.gov/mesh/D001943Q000473 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D016019 http://id.nlm.nih.gov/mesh/D000328
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9410 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_5d445780815638f183c8f68566998507 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2733526 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2187 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9565 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_6d00df506eed78175933b5ecde287c64 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7102

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129769972 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128713593 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129138006

Total number of triples: 68.